What Is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1) is classified as a immune peptide peptide. Enhances T-cell function, boosts dendritic cell activity, and modulates cytokine production. Shifts immune response toward effective pathogen clearance.
It is extensively evaluated in laboratory and clinical settings for its potential to drive immune support, antiviral, recovery. Researchers target Thymosin Alpha-1 for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
Approved in 35+ countries for hep B/C. One of the most extensively studied peptides. Not FDA-approved in US.
How Does Thymosin Alpha-1 Work?
Enhances T-cell function, boosts dendritic cell activity, and modulates cytokine production. Shifts immune response toward effective pathogen clearance.
At the molecular level, Thymosin Alpha-1 operates through pathways characteristic of the Immune Peptide class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with immune support, antiviral, recovery.
Expected Research Timeline
Weeks 2–4
Enhanced immune response to pathogens; reduced frequency of illness
Months 2–3
Sustained immune modulation; improved recovery from illness
Long-Term
Long-term immune resilience; approved use in 35+ countries for hepatitis therapy
What Does the Research Say?
The following are key findings from peer-reviewed studies on Thymosin Alpha-1, indexed on PubMed and equivalent databases:
[1]Thymosin Alpha-1 in immune-compromised patients
Garaci et al.: Review of Tα1 use in immune-compromised patients showing enhanced T-cell function, improved dendritic cell activity, and cytokine modulation.
Evidence: moderate strong[2]Thymosin Alpha-1 safety/efficacy: review of 30+ clinical trials
King & Tuthill: Comprehensive review of 30+ clinical trials involving 11,000+ subjects confirming Tα1's consistent safety and efficacy across hepatitis B/C, cancer, and infections.
Evidence: strong[3]Thymosin Alpha-1 as adjunct in hepatitis B treatment
Mutchnick et al. (Hepatology): Randomized trial showing Tα1 combined with interferon significantly improves virologic response in chronic hepatitis B vs. interferon alone.
Evidence: strong[4]Thymosin Alpha-1 in sepsis and critical care
Evidence review of Tα1 in septic shock, ARDS, and peritonitis showing improved survival and immune recovery in critically ill patients.
Evidence: moderate strong[5]Thymosin Alpha-1 as cancer immunotherapy adjuvant
Garaci et al. (Ann. N.Y. Acad. Sci.): Review of Tα1 as cancer immunotherapy adjunct, showing enhanced chemotherapy tolerance and improved immune recovery in multiple tumor types.
Evidence: moderateSafety & Side Effects
Approved in 35+ countries for hep B/C. One of the most extensively studied peptides. Not FDA-approved in US.
| Side Effect | Incidence | Severity |
|---|---|---|
| Injection site reaction | ~5% of users | mild |
| Mild flu-like symptoms (immune activation) | ~5% of users | mild |
FDA Status: Not Approved for Human Therapeutic Use
Thymosin Alpha-1 is not currently FDA-approved for human use. It is available for research purposes only. Always consult a licensed healthcare provider.
How Is Thymosin Alpha-1 Used?
Route
SubQ
Dose Range
1500–1500 mcg
Frequency
2x/wk
Cycle
12–12 wk
Timing: Any time
Notes: Standard dose: 1.6mg 2x/week. Approved in 35+ countries. Higher doses for active infection.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
Thymosin Alpha-1 vs. Related Compounds
Where to Source Thymosin Alpha-1 for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a immune peptide peptide. Enhances T-cell function, boosts dendritic cell activity, and modulates cytokine production. Shifts immune response toward effective pathogen clearance.
What are the primary research benefits of Thymosin Alpha-1?
Published research identifies primary mechanisms targeting: Immune support, antiviral, recovery. These findings come from 5+ peer-reviewed studies indexed in our database.
What is the half-life of Thymosin Alpha-1?
In published pharmacokinetic data, Thymosin Alpha-1 demonstrates a half-life of approximately 2 hours.
Is Thymosin Alpha-1 FDA approved?
Thymosin Alpha-1 is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is studied under investigational protocols. Always consult a healthcare provider.
What are common side effects of Thymosin Alpha-1?
Reported side effects in published literature include Injection site reaction (~5% of users), Mild flu-like symptoms (immune activation) (~5% of users). Most are classified as mild in severity.
How is Thymosin Alpha-1 administered?
In research settings, Thymosin Alpha-1 is typically administered via SubQ. Standard dose: 1.6mg 2x/week. Approved in 35+ countries. Higher doses for active infection.
Sources
- Thymosin Alpha-1 in immune-compromised patients. View on PubMed
- Thymosin Alpha-1 safety/efficacy: review of 30+ clinical trials. View on PubMed
- Thymosin Alpha-1 as adjunct in hepatitis B treatment. View on PubMed
- Thymosin Alpha-1 in sepsis and critical care. View on PubMed
- Thymosin Alpha-1 as cancer immunotherapy adjuvant. View on PubMed